IINN VS NLSP Stock Comparison

PerformanceSentimentTechnicalsEarningsProfitVolatility
PerformanceSentimentTechnicalsEarningsProfitVolatility

Performance

IINN
10/100

IINN returned -8.60% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.

NLSP
10/100

NLSP returned -3.33% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.

Sentiment

IINN
64/100

IINN had a bullish sentiment score of 63.94% across Twitter and StockTwits over the last 12 months. It had an average of 2.16 posts, 0.42 comments, and 2.10 likes per day.

NLSP

"Sentiment" not found for NLSP

Technicals

IINN
10/100

IINN receives a 10 of 100 based on 14 indicators. 0 are bullish, 12 are bearish.

NLSP
10/100

NLSP receives a 10 of 100 based on 14 indicators. 0 are bullish, 12 are bearish.

Earnings

IINN
100/100

IINN has missed earnings 0 times in the last 20 quarters.

NLSP

"Earnings" not found for NLSP

Profit

IINN
21/100

Out of the last 18 quarters, IINN has had 3 profitable quarters and has increased their profits year over year on 3 of them.

NLSP
10/100

Out of the last 8 quarters, NLSP has had 0 profitable quarters and has increased their profits year over year on 0 of them.

Volatility

IINN
40/100

IINN has had a lower than average amount of volatility over the last 12 months giving it a score of 40 of 100.

NLSP
44/100

NLSP has had a lower than average amount of volatility over the last 12 months giving it a score of 44 of 100.

All score calculations are broken down here to help you make more informed investing decisions

Inspira Technologies Oxy B.H.N. Ltd. Ordinary Shares Summary

Nasdaq / IINN
Healthcare
Medical - Devices
Inspira Technologies Oxy B.H.N. Ltd., a specialty medical device company, engages in the research, development, manufacture, and marketing of respiratory support technology to provide an alternative to invasive mechanical ventilation (MV) for the treatment of respiratory failure. Its lead product is the augmented respiration technology system (ART), a respiratory support system comprising minimally invasive, portable dual lumen cannula, which is inserted into the jugular vein and utilizes extra-corporeal direct blood oxygenation to elevate and stabilize declining oxygen saturation levels. The company was formerly known as Insense Medical Ltd. and changed its name to Inspira Technologies Oxy B.H.N. Ltd. in July 2020. The company was incorporated in 2018 and is based in Ra'annana, Israel.

NLS Pharmaceutics Ltd. Ordinary Shares Summary

Nasdaq / NLSP
Healthcare
Biotechnology
NLS Pharmaceutics AG, a biopharmaceutical company, engages in the discovery and development of therapies for patients with rare and complex central nervous system disorders. The company is focusing on the development of treatments for narcolepsy, idiopathic hypersomnia, and other rare sleep disorders, as well as neurodevelopmental disorders, such as attention deficit hyperactivity disorder (ADHD). Its lead product candidates include Quilience to treat excessive daytime sleepiness and cataplexy; and Nolazol for the treatment of ADHD. The company was incorporated in 2015 and is based in Zurich, Switzerland.